Literature DB >> 15664342

Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.

C P W G M Verweij-van Wissen1, R E Aarnoutse, D M Burger.   

Abstract

A reversed phase high performance liquid chromatography method was developed for the simultaneous quantitative determination of the nucleoside reverse transcriptase inhibitors (NRTIs) lamivudine, didanosine, stavudine, zidovudine and abacavir in plasma. The method involved solid-phase extraction with Oasis MAX cartridges from plasma, followed by high performance liquid chromatography with a SymmetryShield RP 18 column and ultraviolet detection set at a wavelength of 260 nm. The assay was validated over the concentration range of 0.015-5 mg/l for all five NRTIs. The average accuracies for the assay were 92-102%, inter- and intra-day coefficients of variation (CV) were <2.5% and extraction recoveries were higher than 97%. This method proved to be simple, accurate and precise, and is currently in use in our laboratory for the quantitative analysis of NRTIs in plasma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15664342     DOI: 10.1016/j.jchromb.2004.11.019

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  9 in total

1.  Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.

Authors:  Esther J H Janssen; Diane E T Bastiaans; Pyry A J Välitalo; Annemarie M C van Rossum; Evelyne Jacqz-Aigrain; Hermione Lyall; Catherijne A J Knibbe; David M Burger
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

2.  Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.

Authors:  Chiara Piana; Wei Zhao; Kimberly Adkison; David Burger; Evelyne Jacqz-Aigrain; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

3.  Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.

Authors:  Goenke Poerksen; Louisa Pollock; Peter Moons; Emily Chesshyre; David Burger; Saye Khoo; Elizabeth Molyneux
Journal:  Antivir Ther       Date:  2010

4.  Microphysiological flux balance platform unravels the dynamics of drug induced steatosis.

Authors:  Avner Ehrlich; Sabina Tsytkin-Kirschenzweig; Konstantinos Ioannidis; Muneef Ayyash; Anne Riu; Reine Note; Gladys Ouedraogo; Jan Vanfleteren; Merav Cohen; Yaakov Nahmias
Journal:  Lab Chip       Date:  2018-08-21       Impact factor: 6.799

5.  Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.

Authors: 
Journal:  Antivir Ther       Date:  2010

6.  Development and validation of a normal-phase HPTLC method for the simultaneous analysis of Lamivudine and Zidovudine in fixed-dose combination tablets.

Authors:  Palani Venkatesh; Mahesh Daggumati
Journal:  J Pharm Anal       Date:  2011-11-10

7.  Analysis of in vivo absorption of didanosine tablets in male adult dogs by HPLC.

Authors:  Patrícia Severino; Heloisa Silva; Eliana B Souto; Maria Helena A Santana; Teresa Cristina T Dalla Costa
Journal:  J Pharm Anal       Date:  2011-11-10

8.  A stability-indicating LC-MS/MS method for zidovudine: Identification, characterization and toxicity prediction of two major acid degradation products.

Authors:  Prashant S Devrukhakar; M Shiva Shankar; G Shankar; R Srinivas
Journal:  J Pharm Anal       Date:  2017-01-18

9.  Stress Degradation Behavior of Abacavir Sulfate and Development of a Suitable Stability-Indicating UHPLC Method for the Determination of Abacavir, its Related Substances, and Degradation Products.

Authors:  Pallavi Vukkum; Girish R Deshpande; J Moses Babu; R Muralikrishna; Pavani Jagu
Journal:  Sci Pharm       Date:  2012-07-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.